In the United States, waitlist prioritization for liver transplantation (LT) follows urgency-based principles that are meant to only consider pretransplant risk of death.1–3 The Model for End-Stage Liver Disease (MELD) score, when calculated according to laboratory values, has been shown to be a strong predictor of survival benefit, especially in patients with calculated MELD scores of ≥30.4 From a utilitarian perspective, survival benefit, a measure of the combined impact of transplantation on waitlist mortality and posttransplant survival, might be considered a better metric by which to allocate livers.